Moderna gets full US approval for COVID vaccine in children 6 months and older
1. FDA fully approves Spikevax for high-risk children aged 6 months to 11 years. 2. This approval could increase MRNA's revenues and market presence.
FAQ
Why Bullish?
The full approval of Spikevax enhances MRNA's revenue potential, similar to prior approvals boosting stock prices historically. Increased vaccinations in a younger demographic could lead to sustained revenues and market share growth.
How important is it?
The approval directly affects MRNA's product portfolio and financial prospects, making it a significant development.
Why Long Term?
This approval can drive long-term revenue growth, similar to pediatric approvals seen in other vaccines, which contribute to a strong, ongoing demand cycle.